October 12, 2017 8:10am

What goes down, comes up as I’m sticking with the equities I’ve been touting

What’s the gauge of pricing expectation – monetization of information!


No subscription - you’re missing situational awareness! Successful investing and trading means going upstream to obtain and quantify data to qualify actionable intelligence!


Pre-open indications: 4 SELLs and 3 BUYs

Out and about: Spark Therapeutics (ONCE) shares  were halted Thursday as a U.S. FDA committee meets to review the company's gene therapy treatment for patients with vision loss caused by biallelic RPE65-mediated inherited retinal disease, or IRD. IRD is a group of rare blinding conditions caused by one of more than 220 different genes. The FDA committee meeting is set to start at 8.30 a.m. ET and will review the gene therapy Luxturna, which has received orphan drug, breakthrough therapy and rare pediatric disease designations from the agency. The treatment showed positive results in a P3 trial. The committee's ruling is non-binding, but is taken into consideration by the FDA when reviewing drug applications.


Read more because … unless you know what happened yesterday; it is hard to formulate a perspective for today!

Members only. Please login.